Shares of Bio-Techne Corp. plunged 10.89% to $52.20 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.41% to 7,108.40 and Dow ...

TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the ...

Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

A large exercise of company stock options by Robert V Baumgartner, Director at Bio-Techne TECH was disclosed in a new SEC filing on August 27, as part of an insider exercise. What Happened: A notable ...

Bio-Techne Corporation TECH recently announced new advancements in its spatial biology portfolio for the RNAscope ISH technology and the Lunaphore COMET. Research highlights the potential role of ...

Bio-Techne Corporation (NasdaqGS:TECH) is rolling out a new brand architecture centered on three portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The updated structure ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

Shares of Bio-Techne Corp. TECH slipped 2.92% to $51.95 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.04% to 7,135.95 ...

Shares of Bio-Techne Corp. TECH shed 2.90% to $53.51 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.49% to 7,138.80 and Dow ...